02630.HK
Vigonvita Life Sciences Co., Ltd.
HKSE · Healthcare · Drug Manufacturers - General · CN
HKD 75.40
−1.31%Oct 30, 2026, 04:26 UTC
Vigonvita Life Sciences Co., Ltd. said all of its pre-IPO investors, including its controlling shareholders, voluntarily committed not to reduce their holdings during extensions of their lock-up periods by seven or four months.
Source:Aug 28, 2026, 10:13 UTC
Wangshan Wangshui-B (02630.HK) announced interim results for the six months ended June 2026, with revenue of RMB 132 million, up 693.7% year-on-year, and a narrowed loss of RMB 122 million versus a loss of RMB 173 million in the prior-year period.